A Review on Current Treatment of Multiple Sclerosis Disease
Multiple sclerosis is a chronic inflammatory disease of the CNS characterized by the demyelination and axonal loss. The incidence of the MS is increasing worldwide. The underlying cause of MS and mechanisms behind this increase remain opaque, although complex gene, environmental interactions almost certainly play a significant role. The epidemiology of MS indicates the low serum level serum level of vitamin D, smoking and childhood obesity are likely to play a role in disease development. Diagnostic criteria have been adapted to facilitate earlier diagnosis with increased sensitivity and specificity.
2. Koblet G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. MultScler. 2007; 23:1123-1136.
3. Daniel S. Reich et al. Multiple Sclerosis. N Engl J Med. 2018; 378:169-180.
4. Ralf A. Linker, Andrew Chan. Navigating choice in multiple sclerosis management. Neurological research and practice. 2019; 1(5):2-8
5. J.H. Noseworthy et al. MULTIPLE SCLEROSIS. The new England Journal of Medicine. 2000; 343(13):938-958.
6. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13:3-9.
7. Compston A, Coles A. Multiple Sclerosis. Lancet. 2008; 372(9648):1502-1517.
8. NazemGhasemi, Shahnaz Razavi, ElhamNikzad. Multiple Sclerosis: Pathogenesis. Symptoms, Diagnoses and cell-based therap. Cell J. 2017; 19(1):1-10.
9. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008; 255(1):3-11.
10. Gandhi R, LaroniA, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neurol.
11. Kasper LH, Shoemaker J. Multiple Sclerosis immunology: the healthy immune system vs the MS immune system. Neurology. 2010; 74(1):2-8.
12. Brown B. Natalizumab in the treatment of multiple sclerosis. Ther.Clin. Risk Mang. 2009; 5:585-594.
13. Loma I. Heyman R. Multiple Sclerosis: Pathogenesis and treatment. Current Neuropharmacol. 2011; 9(3):409-4.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).